Reduction in major cardiovascular events (SELECT trial, semaglutide) Reduced risk of progressing from prediabetes to type 2 diabetes (Tirzepatide, 3yr trial) Weight reduction significantly improves sleep apnea severity confirmed in multiple GLP-1 trials Emerging ADA 2026 data on GLP-1 anti-inflammatory effects and osteoarthritis improvement Improved basal metabolic rate and energy utilisation, especially with tirzepatides GIP pathway We believe cost transparency is part of quality care
Prescriptions must be issued by a primary care physician or licensed medical doctor practicing within the United States and must be written in English
Hyperglycemia-induced tau cleavage in vitro and in vivo: a possible link between diabetes and Alzheimers disease
The Bottom Line Brand-name and compounded semaglutide deliver the same active ingredient through different regulatory pathways
This article provides evidence-based information to help patients and healthcare professionals navigate this complex topic, emphasising the importance of open communication with prescribers about all substance use
Although GLP-1RAs can attenuate inflammatory tone [105], sustained reductions in nutrient inflow associated with pharmacological weight loss may influence NAD turnover kinetics in metabolically stressed tissues